Some are claiming that the GSK-Vir spike MAB is somehow different from the Lilly and Regeneron spike MABs that did little to nothing to lower the mortality in real-world settings this past winter.. it isn't.

Quote:

---

GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
Move comes after recommendation from independent data and safety monitoring board

Although VIR-7831 met the initial pre-specified criteria to continue to the next phase of the trial, early sensitivity analyses of the first 300 patients enrolled in the trial have ‘raised concerns’ over the potential benefit of the drug in this setting.
As a result, the independent data and safety monitoring board (DSMB) has recommended that enrolment for the VIR-7831 arm of the trial should be paused while the data matures.
“While we are disappointed with the recommendation of the DSMB, we are encouraged by the safety profile of VIR-7831 and by the possibility of a benefit on top of remdesivir and corticosteroids in this advanced cohort of patients,” said George Scangos, chief executive officer of Vir.

---

https://www.pmlive.com/pharma_news/gsk,_vir_h...dy_1364675